Mirae Asset Global ETFs Holdings
BDTX icon

Mirae Asset Global ETFs Holdings’s Black Diamond Therapeutics BDTX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,780
Closed -$36.9K – 3030
2025
Q1 		$36.9K Buy
23,780
+1,014
+4% +$2.13K ﹤0.01% 2899
2024
Q4 		$48.7K Buy
22,766
+2,430
+12% +$6.96K ﹤0.01% 2908
2024
Q3 		$88.5K Buy
+20,336
New +$111K ﹤0.01% 2765

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's BDTX Position: Q2 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Black Diamond Therapeutics (BDTX) in Q2 2025, closing a stake of 23,780 shares — an estimated $36.9K sold.

Mirae Asset Global ETFs Holdings first reported a position in BDTX in Q3 2024 and held it in 3 quarters. The position peaked at $88.5K in Q3 2024. 94 funds tracked by Wall St. Rank hold BDTX as of Q2 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Black Diamond Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 23,780 Black Diamond Therapeutics shares in Q2 2025, an estimated $36.9K.
  • Mirae Asset Global ETFs Holdings first reported a position in Black Diamond Therapeutics in Q3 2024 and held it in 3 quarters.
  • Mirae Asset Global ETFs Holdings's Black Diamond Therapeutics position peaked at $88.5K in Q3 2024.
  • 94 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.